BCR and aneurysmal bone cyst: These BCR mutant bearing tumors are reliant on PI3K signaling to drive NF-κB activation and therefore, targeting the PI3K pathway using isoform-specific inhibitors has resulted in tumor regression in ibrutinib-resistant ABC-DLBCL in vivo models [143].